BiomX Inc. 2Q 2026: Revenue $0.33M, Net loss $3.85M, EPS ($0.36) — 10-Q Summary
BiomX Inc. reported 2Q 2026 revenue of $0.33M, a net loss of $3.85M, and EPS of ($0.36). This marks the company's first quarter of revenue following April acquisitions. The company shifted focus to defense and security markets, with products deployed in pilots and operational sites. Management is pursuing a mixed monetization approach. According to the SEC filing, the company consolidated results from DFSL and ZorroNet from April 2026.
How this was made
The 30-second read
Why it matters
The earnings release provides the first quantitative glimpse of BiomX's new defense‑focused business model, but the small revenue base limits immediate price impact.
Market read
Primary earnings disclosure for a micro‑cap; relevance confined to niche investors tracking early‑stage defense AI firms.
What to watch
Potential upside from government defense spending and AI‑driven security solutions not yet reflected in the current valuation.
Background
BiomX Inc. filed its 10‑Q for Q2 2026, reporting its first recognized revenue after acquiring DFSL and ZorroNet in April.
Market effects
Minimal impact on broader biotech or defense sectors given the company's micro‑cap size and early‑stage revenue.
Limited to U.S. over‑the‑counter biotech investors; no discernible effect on major exchanges.
None
Counterpoint
Despite modest revenue, the shift to defense contracts could signal higher future cash flow if pilots convert to long‑term deals.
Key entities
- CompanyBiomX Inc.
Micro‑cap biotech/defense firm reporting Q2 2026 results.
